<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928289</url>
  </required_header>
  <id_info>
    <org_study_id>SIGHTVISCO-001</org_study_id>
    <nct_id>NCT02928289</nct_id>
  </id_info>
  <brief_title>Randomized Study of the Safety and Effectiveness of the Sight Sciences VISCO™360 Viscosurgical System Versus SLT in Primary Open Angle Glaucoma (VISCO360 Study)</brief_title>
  <official_title>Multi-Center, Prospective, Randomized, Controlled Clinical Evaluation of the Safety and Effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in Canaloplasty Versus Selective Laser Trabeculoplasty in the Reduction of IOP in Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sight Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sight Sciences, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the Sight Sciences
      VISCO™360 Viscosurgical System in reducing intraocular pressure (IOP) in adult, pseudophakic
      subjects with open-angle glaucoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in diurnal IOP (Measured in mm Hg)</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement is performed at 12 months following wash-out of glaucoma medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a ≥ 20% reduction in mean diurnal IOP</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement is performed at 12 months following wash-out of glaucoma medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">497</enrollment>
  <condition>Open-Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>VISCO360 ab interno canaloplasty surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will undergo a surgical procedure in which the VISCO360 Viscosurgical System will be used to microcatheterize and viscodilate Schlemm's canal (i.e., canaloplasty).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selective Laser Trabeculoplasty (SLT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will undergo the SLT procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VISCO360 ab interno canaloplasty surgery</intervention_name>
    <arm_group_label>VISCO360 ab interno canaloplasty surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Selective Laser Trabeculoplasty (SLT)</intervention_name>
    <arm_group_label>Selective Laser Trabeculoplasty (SLT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with primary open-angle glaucoma (POAG) in the study eye.

          -  Pseudophakic with Posterior Chamber IOL (PCIOL)

          -  Able and willing to attend follow up visits for two years post-operative

          -  Able and willing to sign informed consent

        Exclusion Criteria:

          -  Phakia or aphakia

          -  Previous glaucoma procedure with or without an implantable glaucoma device (including
             incisional surgery, ALT, iridectomy/iridotomy, etc.) [Subjects with one prior SLT
             application (&gt;3 months prior to screening) or prior ECP (performed &gt; 12 months prior
             to screening) can be enrolled].

          -  Use of more than 3 ocular hypotensive medications (combination medications count as 2
             medications)

          -  Diagnosis of acute angle closure, traumatic, congenital, malignant, uveitic,
             pseudoexfoliative, pigmentary or neovascular glaucoma

          -  Abnormal angle anatomy as determined by gonioscopy (e.g. peripheral anterior
             synechiae, rubeosis or other angle abnormalities)

          -  Participation in any clinical trial ≤ 30 days prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne-Marie Ripley</last_name>
    <email>anne@sightsciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vold Vision</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinna Rose</last_name>
      <phone>479-442-8653</phone>
      <email>voldresearch@voldvision.com</email>
    </contact>
    <contact_backup>
      <last_name>Iryna Zhukava</last_name>
      <phone>479-442-8653</phone>
      <email>voldresearch@voldvision.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Coastal Vision Medical Group</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashley Owyang, OD</last_name>
      <phone>714-771-1213</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dean McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Almeida</last_name>
    </contact>
    <investigator>
      <last_name>Steven Sarkisian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne Molineaux</last_name>
      <email>jmolineaux@willseye.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>El Paso Eye Surgeons</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axton Supnet</last_name>
      <phone>915-542-0279</phone>
      <email>axton.supnet2462@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Flowers, MD</last_name>
      <phone>817-332-2020</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

